INTRODUCTION
============

Genetic predisposition to both disease susceptibility and host immune response has been postulated. Leprosy disease burden currently is concentrated mainly in six endemic countries; India, Brazil, Myanmar, Madagascar, Nepal, and Mozambique \[[@B1]\]. In India, about 64% of leprosy prevalence and 78% of new case detection of the worlds estimated 719330 cases occur \[[@B1]\]. Studies on Humans have suggested that host genetics is important in disease pathogenesis and protection \[[@B2]\]. With the elucidation of genetics and structure of major histocompatibility complex (MHC), T-cell receptor (TCR), and peptide binding, the role of immune response (Ir) genes and TCR in immune response are generally accepted to be important in active adaptive immunity \[[@B3]\]. The MHC restriction phenomenon has been explained at the "consensus motif" level \[[@B4]\]. India is known for her endogamous, ethnically distinct caste groups, characterized by unique MHC haplotypes \[[@B5], [@B6]\]. Leprosy is a chronic infectious disease caused by *M. leprae*, which manifest as a clinical, pathological, and immunological spectrum with paucibacillary tuberculoid leprosy (TT) at one pole and the multibacillary disseminated lepromatous leprosy (LL) at the other extreme \[[@B7]\]. Epidemiological studies suggest that only a small percentage of people exposed to *M. leprae* get the disease, the majority are resistant and develop effective immunity which arrests the growth of the bacteria at a subclinical stage \[[@B8]\]. Since the first studies in 1848 by Daulelson and Beck, many investigators have attempted to establish a genetic factor that would explain the familial spread of the disease \[[@B9]\]. Studies from India have revealed the HLA-DR2 antigen associations in leprosy patients \[[@B10]\] whereas class I studies are limited. Earlier study from Mumbai in 1982 has shown HLA-B40 association in lepromatous leprosy patients \[[@B11]\]. The present study was undertaken in order to reveal the molecular subtype of the associations.

###### 

High risk HLA class I allele subtypes among the leprosy patients, Mumbai, India.

  ----------- ---------- -------- ---------- -------- -------- -------- ------ ------ -----------------
              Total               Controls                                            
  HLA         *N* = 32            *N* = 67                                            
              *N*+       PF       *N*+       PF       OR       Ki2      EF     Pr F   P value
                                                                                      
  A\*0101     2          0.0625   15         0.2230   0.231    3.965           0.17   0.04
  A\*0203     5          0.1560   2          0.0298   6.018    5.265    0.13          0.02
  A\*0206     7          0.2187   0          0.0000                                   0.000007\*\*
  A\*1102     10         0.3120   1          0.0149   30.000   19.234   0.30          0.00001\*\*
  B\*1801     6          0.1870   2          0.0298   7.500    8.140    0.16          0.007\*\*
  B\*3520     7          0.2187   4          0.0597   4.410    5.546    0.16          0.01
  B\*5110     9          0.2812   0          0.0000                                   0.0000005\*\*
  B\*52011    6          0.1875   6          0.0890   2.346    1.950    0.10          0.16
  Cw\*03031   1          0.0300   10         0.1490   0.183    3.053           0.12   0.08
  Cw\*04011   1          0.0310   22         0.3280   0.065    10.718          0.30   0.001\*\*
  Cw\*0407    14         0.4375   0          0.0000                                   0.000000001\*\*
  Cw\*0602    4          0.1250   25         0.3730   0.240    6.437           0.28   0.01
  Cw\*0703    8          0.2500   0          0.0000                                   0.000001\*\*
                                                                                      
  ----------- ---------- -------- ---------- -------- -------- -------- ------ ------ -----------------

  ------ ---------------------------------- ------ ---------------------
  *N*+   Positive number                    OR     Odds ratio
  PF     Phenotype frequency                Pr F   Preventive fraction
  EF     Etiological fraction               \*\*   Significant P value
  Ki2    Chi square with Yates correction          
  ------ ---------------------------------- ------ ---------------------

MATERIALS AND METHODS
=====================

Patients and controls
---------------------

Thirty-two leprosy patients attending the dermatology clinic, in various hospitals in Mumbai, Maharastra, were studied for HLA A, B, and C alleles and compared with 67 unrelated healthy normal controls from the same endemic region. All the patients included in the study were HIV negative and were being treated with chemotherapy. The controls did not show any clinical symptoms of leprosy. The mean age of the controls was 40 years.

HLA typing
----------

Genomic DNA was extracted by sodium acetate method \[[@B12]\] from 5 ml of EDTA blood. These Genomic DNA were genotyped for their A, B, and C allele subtypes by polymerase chain reaction reverse line strip sequence-specific oligonucleotide hybridization (PCR-RLS-SSOP) strips (Roche Molecular, Oakland, Calif, USA) \[[@B13]\]. Each strip for HLA A typing carried a total of 57 immobilized sequence-specific oligos (SSOs), while the B carried a total of 84 immobilized SSOs. Genomic DNA was amplified using HLA A or HLA B locus specific biotinylated primers and hybridized with the SSO strips. Streptavidin-conjugated alkaline phosphatase was used as a conjugate for positive color development using bromochloroindolyl phosphate/nitrobluetetrazolium (BICP/NBT) in dimethylformamide (DMF) as a substrate. The alleles were determined using the pattern interpretation software supplied along with the kit.

Statistical analysis
--------------------

The phenotype frequencies, odds ratio, probability value, chi square with Yates correction, and aetiological and preventive fraction were estimated using our database and computer programs as described earlier \[[@B14]\]. Since each individual is tested for several HLA alleles and the same data used for comparing the frequency; it is possible that one of the alleles will by chance deviate significantly. To overcome this error, the P value is corrected by the use of Bonferroni inequality method \[[@B15]\], that is, by multiplying it with the number of alleles compared.

RESULTS AND DISCUSSION
======================

Some significant findings can be concluded from this study. (1) HLA A\*0101, Cw\*04011, and Cw\*0602 subtypes were found to be negatively associated with leprosy patients, when compared with controls ([Table 1](#T1){ref-type="table"}). (2) A\*0206, A\*1102, B\*4016, B\*5110, Cw\*0407, and Cw\*0703 alleles were associated with the leprosy patients when compared to controls. ([Table 1](#T1){ref-type="table"}). (3) Haplotype A\*1102-B\*4006-Cw\*1502 was found to be associated with lepromatous leprosy patients significantly when compared to controls. Various epidemiological studies in the past have suggested that in prolonged contact with lepromatous leprosy patients only less than 2% of the contact develops Lepromatous leprosy. In the present study, A\*1102-B\*4006-Cw\*1502 is correlated positively and strongly with lepromatous leprosy, and this haplotype constitutes less than 3% of the control population as expected. Further DRB1 gene typing by PCR-SSP typing revealed that 83% of these haplotypes were found to posses DRB1\*1501 allele. Some of these associations and protection have not been previously described in the leprosy patients studied from India. HLA A\*1102, B\*1801, and B\*3520 were significantly increased when compared to the controls. It was interesting to note that A\*2413, B\*0706, B\*4016, Cw\*0708, and Cw\*1505 were significantly associated with the lepromatous leprosy patients while they were not associated with tuberculoid type of leprosy when compared to controls. HLA B\*5110, Cw\*0407, and Cw\*0703 were significantly associated with leprosy patients while A\*0206 was significantly associated with the tuberculoid leprosy patients when compared to the controls. The significant haplotypes associated with the leprosy patients when compared to the controls revealed that A\*1102-B\*4006-Cw\*1502 was the significant haplotype associated with lepromatous leprosy ([Table 2](#T2){ref-type="table"}). Further haplotypes A\*1102-B\*4006-Cw\*0407 and A\*0203-B\*4016-Cw\*0703 were increased among both the lepromatous and tuberculoid type of leprosy patients when compared to controls.

Differences in disease susceptibility can be seen at the level of individuals and populations. Genetic epidemiology data indicates that there might be major susceptibility genes that account for a significant proportion of genetic contribution to disease susceptibility. HLA loci evolve very fast, probably as a result of selective pressure from pathogens, and polymorphism in these loci has been associated with altered susceptibility to infectious diseases \[[@B16]\]. Nevertheless, convincing results have been obtained from studies on HLA class II associations with leprosy \[[@B10]\], however, data on HLA Class I associations is limited and inconsistent. In leprosy patients from Iran, HLA B35 was increased, while A1 was decreased in lepromatous leprosy patients \[[@B17]\]. Leprosy patients from Thailand showed HLA B18 and B40 associations in lepromatous leprosy \[[@B18]\]. Haplotypes A2-B40, A11-B40, and A24-B40 were frequent among South Indian leprosy patients \[[@B19]\]. HLA B40 was significantly associated with Mumbai lepromatous leprosy patients \[[@B11]\]. HLA A11 and A33 were increased among Korean leprosy patients \[[@B20]\]. HLA A11 was significantly increased with erythema nodosum leprosum (ENL) leprosy patients from North India \[[@B21]\]. Lepromatous Leprosy patients from North India showed increased frequencies of HLA B60, DR2, DR8, and DQw1 \[[@B22]\]. Increased frequencies of HLA A2, A11, B40, and DR2 were observed among the leprosy patients from South India \[[@B23]\]. Recently, HLA A9, A10, A32, B5, B21, Bw4, Bw6, Cw1, and Cw2 were found to be significantly more frequent among Turkish leprosy patients \[[@B24]\]. In all these earlier studies, the HLA were determined by conventional techniques that might have resulted in a lower resolution of HLA types. The development of DNA-based HLA typing methods has improved the validity of HLA typing. We have employed the high resolution PCR-RLS-SSOP typing to define the HLA class I alleles among the Mumbai leprosy patients. Hence, we have identified novel alleles associated with Mumbai leprosy patients.

###### 

Two Significant haplotypes associated with the leprosy patients, Mumbai, India.

  -------------------------- ---------------------- ---------- ------- -------------- ---------- ------- ---------
  Haplotype                  Percentage frequency                                                        
                                                                                                         
                             Control                LL type    OR      P value        BT type    OR      P value
                             *N* = 67               *N* = 16                          *N* = 16           
  A\*11-B\*40                7.46                   50.00      12.40   0.0001\*\*     12.50      1.770   0.514
  A\*1102-B\*4006-Cw\*1502   2.98                   31.25      12.51   0.000025\*\*   0.00       0.000   0.000
  A\*1102-B\*4006-Cw\*0407   1.49                   12.50      9.44    0.0037\*\*     6.25       4.400   0.264
  A\*02-B\*40                20.89                  31.25      1.72    0.375          18.75      0.873   0.514
  A\*0203-B\*4016-Cw\*0703   1.49                   12.50      9.43    0.034          6.25       4.400   0.264
                                                                                                         
  -------------------------- ---------------------- ---------- ------- -------------- ---------- ------- ---------

  ------ ---------------------
  OR     Odds ratio
  \*\*   Significant P value
  ------ ---------------------
